The DOI matches its Crossref record; 232 of the 244 references it cites were found in a registry or an index.
Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a minimal difference between its incidence rate and mortality rate. Advances in oncology over the past several decades have dramatically improved the overall survival of patients with multiple cancers due to the implementation of new techniques in early diagnosis, therapeutic drugs, and personalized therapy. However, pancreatic cancers remain recalcitrant, with a 5-year relative survival rate of <9%. The lack of measures for early diagnosis, strong resistance to chemotherapy, ineffective adjuvant chemotherapy and the unavailability of molecularly targeted therapy are responsible for the high mortality rate of this notorious disease. Genetically, PDAC progresses as a complex result of the activation of oncogenes and inactivation of tumor suppressors. Although next-generation sequencing has identified numerous new genetic alterations, their clinical implications remain unknown. Classically, oncogenic mutations in genes such as KRAS and loss-of-function mutations in tumor suppressors, such as TP53, CDNK2A, DPC4/SMAD4, and BRCA2, are frequently observed in PDAC. Currently, research on these key driver genes is still the main focus. Therefore, studies assessing the functions of these genes and their potential clinical implications are of paramount importance. In this review, we summarize the biological function of key driver genes and pharmaceutical targets in PDAC. In addition, we conclude the results of molecularly targeted therapies in clinical trials and discuss how to utilize these genetic alterations in further clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS and GNAS mutations are known to drive the progression of IPMNs [43].”
From Artificial Intelligence in the Diagnosis and Treatment of Pancreatic Cystic Lesions and Adenocarcinoma (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pancreatic cancer commonly features mutations in key genes, such as KRAS, p16/CDKN2A, TP53 and SMAD4/DPC4 [3,4,5] (Table 1).”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [5]
In the citing paper
“Co-occurrence of other mutations were common in PDAC”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [47]
In the citing paper
“the disease progression model proposed based on observed co-mutation patterns was early KRAS mutation followed by CDKN2A then loss of TP53 and SMAD447,48”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–232 of 232
Harinck, F., Kluijt, I., van Mil, S. E., Waisfisz, Q., van Os, T. A. M., Aalfs, C. M., Wagner, A., Olderode-Berends, M. J. W., Sijmons, R. H., Kuipers, E. J., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.226 · Cited by 42
Genomic testing for pancreatic cancer in clinical practice as real-world evidence
Hayashi, H., Tanishima, S., Fujii, K., Mori, R., Okamura, Y., Yanagita, E., Matsuoka, R., Amano, T., Kinoshita, I., Komatsu, Y., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.07.006 · Cited by 40
PROPPER, D. J., Давиденко, І., Bridgewater, J. A., Kupčinskas, L., Fittipaldo, A., Hillenbach, C., Klughammer, B., & Ducreux, M. P. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu176 · Cited by 39
Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.001 · Cited by 39
Self-citationEUS-FNA Mutational Analysis in Differentiating Autoimmune Pancreatitis and Pancreatic Cancer
Khalid, A., DeWitt, J. M., Ohori, N. P., Chen, J.-H., Fasanella, K. E., Sanders, M. K., McGrath, K. M., & Nikiforova, M. N. (2011) · Pancreatology · doi:10.1159/000331505 · Cited by 37
Duong, H., Hong, Y. B., Kim, J. S., Lee, H., Yi, Y. W., Kim, Y. J., Wang, A., Zhao, W., Cho, C., Seong, Y., et al. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12101 · Cited by 35
Hong, E., Park, S., Ooshima, A., Hong, C. P., Park, J., Heo, J. S., Lee, S., An, H., Kang, J. M., Park, S. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59893-5 · Cited by 35
Moser, C., Lang, S. A., Hackl, C., Wagner, C., Scheiffert, E., Schlitt, H. J., Geissler, E. K., & Stoeltzing, O. (2012) · PubMed · Cited by 35
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
Cardin, D. B., Goff, L. W., Li, C., Shyr, Y., Winkler, C. F., DeVore, R. F., Schlabach, L., Holloway, M., McClanahan, P., Meyer, K. D., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.208 · Cited by 34
Kordes, S., Richel, D. J., Klümpen, H., Weterman, M. J., Stevens, A. J. W. M., & Wilmink, J. W. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9802-1 · Cited by 34
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
Renouf, D. J., Hedley, D. W., Krzyzanowska, M. K., Schmuck, M., Wang, L., & Moore, M. J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3102-y · Cited by 32
Temraz, S. N., Shamseddine, A. I., Mukherji, D., Charafeddine, M., Tfayli, A., Assi, H. I., Hammoud, M. S., Makki, I., & Nassif, S. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0464-y · Cited by 32
Striefler, J. K., Sinn, M., Pelzer, U., Jühling, A., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Dörken, B., Oettle, H., et al. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.001 · Cited by 31
Wrana, J. L. (2009) · Cell · doi:10.1016/j.cell.2008.12.028 · Cited by 30
ATM Serine/Threonine Kinase and its Role in Pancreatic Risk
Nanda, N., & Roberts, N. J. (2020) · Genes · doi:10.3390/genes11010108 · Cited by 30
Baumgart, M., Werther, M., Bockholt, A., Scheurer, M., Rüschoff, J., Dietmaier, W., Ghadimi, Β. M., & Heinmöller, E. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181dc62f6 · Cited by 29
Palacio, S., McMurry, H. S., Ali, R. A., Donenberg, T. R., Silva‐Smith, R., Wideroff, G. A., Sussman, D. A., Lima, C. M. S. R., & Hosein, P. J. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.09.12 · Cited by 29
Senescence in pancreatic carcinogenesis: from signalling to chromatin remodelling and epigenetics
Singh, S. K., & Ellenrieder, V. (2013) · Gut · doi:10.1136/gutjnl-2012-302793 · Cited by 29
Wrzeszczyński, K. O., Rahman, S., Frank, M. O., Arora, K. S., Shah, M. J., Geiger, H. M., Felice, V., Manaa, D., Dikoglu, E., Khaira, D., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a004424 · Cited by 27
Karavasilis, V., Samantas, E., Koliou, G.-A., Kalogera-Fountzila, A., Pentheroudakis, G., Varthalitis, I., Linardou, H., Rallis, G., Skondra, M., Papadopoulos, G., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0605-y · Cited by 27
Wang, H., Stephens, B. J., Hoff, D. D. V., & Han, H. (2009) · Pancreas · doi:10.1097/mpa.0b013e31819d7415 · Cited by 21
Kawamura, D., Takemoto, Y., Nishimoto, A., Ueno, K., Hosoyama, T., Shirasawa, B., Tanaka, T., Kugimiya, N., Harada, E., & Hamano, K. (2017) · Oncology Reports · doi:10.3892/or.2017.5974 · Cited by 19
Luo, Y., Tian, L., Ye, F., Miaoying, Y., Chen, X., & Huang, Q. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9555-3 · Cited by 17
O’Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J. M., Coveler, A. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw095 · Cited by 16
Lee, J. W., Lee, J. H., Shim, B. Y., Kim, S. H., Chung, M.-J., Kye, B., Kim, H. J., Cho, H., & Jang, H. S. (2015) · Medicine · doi:10.1097/md.0000000000001284 · Cited by 15
Kamphues, C., Bova, R., Bahra, M., Klauschen, F., Muckenhuber, A., Sinn, B. V., Warth, A., Goeppert, B. F., Endris, V., Neuhaus, P., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000248 · Cited by 12
Azzopardi, S., Pang, S., Klimstra, D., & Du, Y. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.003 · Cited by 11
Vitellius, C., Eymerit-Morin, C., Luet, D., Fizanne, L., Foubert, F., Bertrais, S., Rousselet, M., & Caroli‐Bosc, F. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0522-3 · Cited by 11
Park, D., Shakya, R., Koivisto, C. S., Pitarresi, J. R., Szabolcs, M. J., Kladney, R. D., Hadjis, A. D., Mace, T. A., & Ludwig, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226714 · Cited by 10
Makielski, R., Lubner, S. J., Mulkerin, D. L., Traynor, A. M., Groteluschen, D. L., Eickhoff, J. C., & LoConte, N. K. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2783-y · Cited by 10
SUS--SOS? Society of University Surgeons. Save Our Society.
Lillemoe, K. D. (1998) · PubMed · Cited by 7
Presidential address: SUS — SOS?
Lillemoe, K. D. (1998) · Surgery · doi:10.1016/s0039-6060(98)70111-4 · Cited by 7
Research works printed but not linked: 1
- Wilentz RE, Chung CH, Sturm PD, Musler A, Sohn TA, Offerhaus GJ, et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer-Am Cancer Soc. 1998;82:96–103.
Cited by
Sorted by citations
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
A Comprehensive Review of Deep Learning Applications with Multi-Omics Data in Cancer Research
Sartori, F., Codicè, F., Caranzano, I., Rollo, C., Birolo, G., Fariselli, P., & Pancotti, C. (2025) · Genes · doi:10.3390/genes16060648 · Cited by 76
Roles of microbiota in pancreatic cancer development and treatment
Cruz, M. S., Tintelnot, J., & Gagliani, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320280 · Cited by 59
Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2/GPX4 axis
Liu, X., Peng, X., Cen, S., Yang, C., Ma, Z., & Shi, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1129662 · Cited by 52
Metadata
- Authors
- Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- ORCID
- Qin, Yi
- Venue
- Acta Pharmacologica Sinica
- Published
- 2021-02-11
- Volume
- 42
- Issue
- 11
- Pages
- 1725-1741
- ISSN
- 0253-9756 (ISSN-L)
- 1671-4083
- 1745-7254
- PMC
- PMC8563973
- OpenAlex
- W3126704571
- Cited by
- 149
- References
- 244
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 50 · 2023: 25 · 2022: 9 · 2021: 3
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Acta Pharmacologica Sinica (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation (81625016)
- National Natural Science Foundation of China (81871950 and 81972250, 2019-01-07-00-07-E00057, 81625016, 81871950, 2019-01, 81972250)
- National Science Fund for Distinguished Young Scholars (81625016)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic ductal adenocarcinoma, driver genes, KRAS mutation, TP53, CDKN2A, SMAD4, BRCA2, oncogene activation, tumor suppressor inactivation, targeted therapy, drug resistance, next-generation sequencing, clinical trials, personalized treatment
- MeSH terms
- Clinical Trials as Topic, Humans, Mutation, Oncogenes, Pancreatic Neoplasms, Biomarkers, Tumor, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Smad4 Protein, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
